FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival

Jácome, Alexandre A.; Kee, Bryan K.; Fogelman, David R.; Dasari, Arvind; Shureiqi, Imad; Raghav, Kanwal; Morris, Van K.; Johnson, Benny; Overman, Michael J.; Wolff, Robert A.; Kopetz, Scott; Rogers, Jane E.; Ahmed, Shahab; Mehdizadeh, Amir; Rothschild, Nicole D.; Eng, Cathy

doi:10.1016/j.clcc.2020.05.010

Cited by 4 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 21 , 22 In a study comparing outcomes of treatment with folinic acid, fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) to doublet therapy, the median age of patients receiving FOLFOXIRI was 46 years, and no survival gain was noted as well. 44 Access to targeted therapies is very limited in all institutions.…”

Section: Discussionmentioning

confidence: 99%

Early-Onset Colorectal Cancer in Egypt: Pathological Characters, Patterns of Care, and Survival Compared to Average-Age Onset Colorectal Cancer: A Retrospective Multicenter Study

Rashad,

Eid Salem,

Meheissen

et al. 2024

JCO Glob Oncol

View full text Add to dashboard Cite

PURPOSE Early-onset colorectal cancer (EOCRC) is a rising health problem. The incidence of EOCRC has increased over the past 2 decades all over the world. Reports from Egypt since the 1990s have reported a higher incidence among young populations with no identifiable risk factors. The aim of this study was to assess EOCRC in Egypt regarding incidence, characteristics, treatment pattern, and survival compared with average age onset and elderly patients. MATERIALS AND METHODS This was a retrospective, record-based, cohort study combining data from four different cancer centers in Egypt. We grouped patients according to age into three categories: the EOCRC group for patients age ≤45 years and the average age onset and elderly cancer group (for patients age ≥65 years). RESULTS The study included 1,310 patients with histopathologically proven colorectal cancer, representing four different geographical areas in Egypt. Patients with EOCRC represented 42.4% of the study population. Female patients were 50.6% among the EOCRC group and 52.5% among the average age group. Rectal tumors were significantly higher in EOCRC (54.7% v 40.6%; P < .001). There was no significant difference between both groups regarding the tumor stage at presentation, obstruction, or presence of metastases at presentation. Patients with EOCRC had a significantly higher rate of peritoneum/adnexa metastases than the average age ones (12.3% in EOCRC v 6.9% in the average age group; P < .001). No statistically significant differences between EOCRC and average age groups in both disease-free survival and overall survival were reported. CONCLUSION A comprehensive framework for the study of EOCRC is required in Egypt as well as a genomic analysis to identify possible underlying genetic alterations responsible for the high incidence of EOCRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Early-Onset Colorectal Cancer in Egypt: Pathological Characters, Patterns of Care, and Survival Compared to Average-Age Onset Colorectal Cancer: A Retrospective Multicenter Study

Rashad,

Eid Salem,

Meheissen

et al. 2024

JCO Glob Oncol

View full text Add to dashboard Cite

show abstract

“…Nevertheless, FOLFOXIRI with or without bevacizumab remains a viable option in right-sided BRAF-mutant mCRC patients [ 135 ]. Based on a retrospective analysis involving 196 patients with treatment-naïve right-sided mCRC, younger patients received triplet regimens more often but underwent fewer subsequent therapies (61% versus 78%, p = 0.043) [ 136 ]. Pooled analysis of the TRIBE and TRIBE2 studies demonstrated that intensification of upfront backbone chemotherapy in younger patients (<50 years) had a lower risk of G3-4 neutropenia, diarrhea, and asthenia and a higher risk of nausea and vomiting, with no significant survival benefit difference between the two age cohorts [ 137 ].…”

Section: Treatmentmentioning

confidence: 99%

Early Onset Metastatic Colorectal Cancer: Current Insights and Clinical Management of a Rising Condition

Medici,

Riccò,

Caffari

et al. 2023

Cancers

View full text Add to dashboard Cite

Despite a recent overall decrease in colorectal cancer (CRC) incidence and mortality, there has been a significant rise in CRC diagnoses in young adults. Early onset colorectal cancer (EOCRC) is defined as CRC diagnosed before the age of 50. Possible predisposing conditions include not only genetic syndromes but also other risk factors, such as microbiome alteration, antibiotic exposure, obesity, diabetes mellitus, and inflammatory bowel disease. EOCRC tends to be diagnosed later than in the older counterpart because of a lack of awareness and the fact that screening for CRC usually starts at the age of 50. Furthermore, CRC in young adults seems to be related to unique molecular features and more aggressive clinical behavior. This paper aims to provide an in-depth review of this poorly understood subject, with a comprehensive review of the state of the art and considerations for future perspectives.

show abstract

A comprehensive framework for early-onset colorectal cancer research

Eng

Jácome²,

Agarwal

et al. 2022

The Lancet Oncology

View full text Add to dashboard Cite

FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival

Cited by 4 publications

References 25 publications

Early-Onset Colorectal Cancer in Egypt: Pathological Characters, Patterns of Care, and Survival Compared to Average-Age Onset Colorectal Cancer: A Retrospective Multicenter Study

Early-Onset Colorectal Cancer in Egypt: Pathological Characters, Patterns of Care, and Survival Compared to Average-Age Onset Colorectal Cancer: A Retrospective Multicenter Study

Early Onset Metastatic Colorectal Cancer: Current Insights and Clinical Management of a Rising Condition

A comprehensive framework for early-onset colorectal cancer research

Contact Info

Product

Resources

About